HC Wainwright Decreases Earnings Estimates for Urogen Pharma

Urogen Pharma (NASDAQ:URGN) – Equities researchers at HC Wainwright lowered their Q2 2025 EPS estimates for Urogen Pharma in a report issued on Monday, June 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.80) for the quarter, down from their prior estimate of ($0.74). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.43 EPS.

URGN has been the topic of several other research reports. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the company a “neutral” rating in a report on Friday. Scotiabank reaffirmed an “outperform” rating on shares of Urogen Pharma in a research note on Friday. Guggenheim reaffirmed a “buy” rating and set a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Urogen Pharma in a research note on Thursday, June 12th. Finally, Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Urogen Pharma currently has a consensus rating of “Buy” and a consensus target price of $32.86.

Urogen Pharma Stock Performance

NASDAQ:URGN opened at $13.24 on Wednesday. The company has a current ratio of 5.65, a quick ratio of 5.47 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $610.50 million, a price-to-earnings ratio of -4.16 and a beta of 0.40. The firm’s fifty day simple moving average is $8.69 and its 200 day simple moving average is $10.07. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $18.15.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the business’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider now directly owns 153,378 shares of the company’s stock, valued at $1,130,395.86. The trade was a 3.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is currently owned by company insiders.

Institutional Trading of Urogen Pharma

Institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after purchasing an additional 2,983,368 shares in the last quarter. RTW Investments LP raised its holdings in shares of Urogen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock worth $40,841,000 after purchasing an additional 47,447 shares in the last quarter. RA Capital Management L.P. bought a new stake in shares of Urogen Pharma in the 1st quarter worth approximately $35,461,000. Vestal Point Capital LP raised its holdings in shares of Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock worth $23,812,000 after purchasing an additional 522,957 shares in the last quarter. Finally, Toronto Dominion Bank bought a new stake in shares of Urogen Pharma in the 4th quarter worth approximately $18,628,000. 91.29% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.